KIT (KIT proto-oncogene, receptor tyrosine kinase)

Adjuvant tyrosine kinase inhibitors, such as imatinib, are reserved for high-risk lesions or unresectable tumors. This case highlights the importance of considering GIST as a differential diagnosis in obscure upper GI bleeding. It also demonstrates that laparoscopic resection is a safe and effective treatment option for ileal GISTs, even in the context of acute bleeding.

Although it's in the favorable risk stratification category (NCCN Clinical Practice Guidelines 2023), the presence of complex abnormalities, including 1q+, deletion of 12p, and a der(12;22), suggests genomic instability and poor prognosis. The patient died six months post-transplant.

The study also showed the inherent resistance of the KIT p.Ala829Pro mutation to imatinib, explaining the failure of subsequent treatment. This study highlights the significant spatial and temporal heterogeneity of acral melanoma and underscores the critical importance of serial biopsies in accurately capturing clonal dynamics and guiding precision oncology therapy.

P2, N=25, Recruiting, University of California, San Francisco | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027

RNA-Seq demonstrates high accuracy for detecting clinically relevant KIT and PDGFRA mutations and may complement DNA-based profiling. The DNA cohort provides broader context for mutation prevalence and patterns in clinical practice.

Immunohistochemistry remains indispensable for diagnosis, with DOG1 demonstrating superior sensitivity. These findings reinforce the critical role of integrated histopathological and immunohistochemical evaluation in the accurate diagnosis and management of GISTs.

This case highlights an under-recognized presentation of infantile mastocytoma, emphasizing the importance of clinical awareness and histopathological confirmation. Accurate diagnosis allows appropriate reassurance for caregivers, while long-term monitoring ensures early detection of any rare progression to systemic mastocytosis.

On follow-up PET-CT scan after imatinib therapy, the patient showed a complete/near complete metabolic response. This report expands the imaging spectrum of PHGIST and emphasizes the importance of radiologic-pathologic correlation in distinguishing this rare lesion from metastatic liver disease.

The patient achieved sustained remission after surgery and chemotherapy during a follow-up period of five years and six months. This case underscores the significant diagnostic challenge posed by dysgerminomas mimicking sex cord-stromal tumors and highlights the critical role of an integrated diagnostic approach combining morphology, immunohistochemistry, and molecular profiling to avoid misdiagnosis and guide management.

To determine whether epigenetic cytosine modifications influence G4-ligand interactions, CD melting experiments were also performed in the presence of a panel of HDAC inhibitors. Among the tested compounds, one ligand produced the most pronounced increase in G4 thermal stability, identifying it as a promising candidate for selective G4 targeting.

Core-binding factor (CBF) acute myeloid leukemia (AML) with t(8;21)(q22;q22)/RUNX1::RUNX1T1 is typically considered as a favorable-risk AML in the context of cytarabine-based intensive chemotherapy...Here, we report the case of a young patient diagnosed with CBF-AML and RUNX1::RUNX1T1 fusion gene, carrying a rare and complex three-way t(8;11;21)(q22;q13;q22) translocation, with mutated KIT, ASXL1 and TET2 genes, transforming into an aggressive and multi-refractory mediastinal myeloid sarcoma. This case illustrates that this scarcely reported variant might negatively impact the favorable prognosis of CBF-AML.

Notably, compound 5 exhibits superior anti-proliferative activity against HepG2 cells compared to doxorubicin (DOX) and Gefitinib, with markedly reduced cytotoxicity toward normal cells. In vivo efficacy was confirmed in a zebrafish xenograft model, where compound 5 significantly suppressed tumor proliferation. These findings establish compound 5 as a potent EGFR G4 DNA stabilizer that exerts multi-level anti-tumor effects through targeted modulation of this macromolecular structure, offering a promising lead for EGFR G4-directed liver cancer therapy.